What Enhancement Actually Means

Dr. Leila Ahmadi is 52, a neurologist at the University of Washington Memory and Brain Wellness Center, and she prescribes exercise before she prescribes anything else. Her patients argue with her. They want a pill. She tells them: the most effective cognitive enhancement intervention available to any human being at any age is thirty minutes of moderate aerobic exercise five days a week, it costs nothing, and it works better than anything she can write a prescription for.

Her patients do not want to hear this. They have seen the advertisements for brain supplements. They have read about the drugs. They want the intervention that comes in a bottle and works while they sit still. Dr. Ahmadi has been having this conversation for twenty years. She has kept track of her patients, informally, the way clinicians do. The ones who listened and exercised are doing better than the ones who argued and bought supplements. She does not claim that the exercise prevented Alzheimer’s for any of them. She claims that the difference in their trajectories is not subtle.

What “Enhancement” Actually Means

#

The word “enhancement” covers a spectrum that most discussions collapse into a single promise. The spectrum has three distinct zones, and the zone determines what is possible.

Compensation is what scaffolding provides: external support that bridges the gap between what the person can do and what the environment requires. The labeled cabinet from BML-05.01 is compensation. It does not improve cognitive function. It reduces the cognitive demand of the task. This is the zone where most practical interventions for people with moderate to advanced dementia operate.

Preservation is slowing the rate of decline. An intervention that does not improve function above baseline but slows the trajectory, extending the period of current function, is a preservation intervention. Cholinesterase inhibitors like donepezil operate in this zone for some patients. The effect is symptomatic and modest. The disease continues to progress. The progression is slightly slower for some people.

Genuine enhancement is improvement above current baseline. Stronger memory. Faster processing. Better executive function than the person had last month. In the context of active dementia, genuine enhancement is modest at best. In the context of mild cognitive impairment, it is more achievable. In the context of healthy aging, it is the most available it will ever be. The window for genuine enhancement narrows as the disease progresses, which is the argument for starting early and the argument against false promises to people with advanced disease.

Exercise: The One That Works

#

One hundred fifty minutes per week of moderate aerobic exercise produces measurable hippocampal volume preservation in people over 65 across multiple randomized controlled trials. The mechanism is specific: aerobic exercise stimulates the release of brain-derived neurotrophic factor (BDNF), which promotes neurogenesis in the hippocampus, the brain region most critical for memory formation and most vulnerable to Alzheimer’s pathology. This is the only widely available intervention with this specific mechanism at this price point.

The evidence is not ambiguous. A landmark trial published in the Proceedings of the National Academy of Sciences showed that older adults who engaged in aerobic exercise for one year increased hippocampal volume by approximately 2%, effectively reversing one to two years of age-related volume loss. The control group, which did stretching and toning, showed the expected decline.

The catch is that the intervention requires effort, consistency, and time. Exercise three times and stop produces no lasting benefit. Exercise for six months produces structural brain changes that persist. There is no shortcut with a biological mechanism good enough to overcome sedentary living. Dr. Ahmadi tells her patients this plainly: there is nothing she can prescribe that will outperform what their own legs can do.

Sleep: The Enhancement Nobody Discusses

#

The glymphatic system clears amyloid beta and tau proteins from the brain primarily during deep sleep. These are the proteins that accumulate in Alzheimer’s disease. Chronic sleep deprivation impairs glymphatic clearance, allowing toxic proteins to accumulate faster. The relationship is documented across multiple studies and is dose-dependent: worse sleep predicts faster cognitive decline.

Improving sleep quality is not a wellness recommendation. It is a cognitive intervention with a specific and documented mechanism. Sleep hygiene practices, treatment of sleep apnea, melatonin supplementation for circadian rhythm support, and reduction of medications with sleep-disrupting side effects are all interventions that can improve deep sleep duration and, through the glymphatic pathway, reduce the accumulation of neurotoxic proteins.

The person who is not sleeping well and has not addressed it is accepting a modifiable risk factor for accelerated cognitive decline. The conversation with the physician about sleep should be as urgent as the conversation about exercise. It is rarely prioritized as such.

The Nootropics Market

#

The market for brain supplements exceeds $8 billion annually in the United States. Most of what it sells does not work.

Ginkgo biloba, the most widely sold cognitive supplement globally, has weak to no evidence for meaningful cognitive enhancement in well-powered randomized controlled trials. The largest trial, the GEM study with over 3,000 participants, found no significant effect on the rate of cognitive decline or the incidence of dementia.

Phosphatidylserine, Prevagen (apoaequorin), and most supplements marketed as “brain health” products have insufficient evidence from rigorous trials to support their marketing claims. The Federal Trade Commission has taken enforcement action against specific brands for deceptive advertising.

There are a few interventions with modest specific evidence. Omega-3 fatty acids show some benefit for specific subpopulations, particularly people with low baseline omega-3 levels and specific genetic profiles. B-vitamins reduce homocysteine, and elevated homocysteine is associated with faster cognitive decline; supplementation benefits the subpopulation with elevated homocysteine, not everyone. The distinctions matter: a supplement that helps a specific subpopulation is different from a supplement that helps everyone, and the marketing rarely makes this clear.

What Technology Is Coming

#

Transcranial direct current stimulation (tDCS) delivers low electrical current to specific brain regions through electrodes placed on the scalp. Some FDA-cleared devices are available for home use. The evidence shows modest but real effect sizes for specific cognitive functions: working memory, processing speed, and attention. The effects are not large. They are not consistent across all users. The technology is real but limited.

Neurofeedback uses real-time displays of brain activity to train self-regulation of brain function. The evidence for cognitive improvement through neurofeedback is growing, with some positive results for attention and executive function. Consumer devices are becoming more accessible. The evidence base is not yet strong enough to recommend neurofeedback as a primary cognitive enhancement strategy.

Closed-loop brain stimulation systems, which deliver personalized neurostimulation based on real-time EEG feedback, are in clinical development. The concept is promising: instead of generic stimulation, the system reads the brain’s current state and delivers stimulation calibrated to the individual’s neural needs in that moment. These systems are three to five years from consumer availability and represent the most credible high-technology enhancement approach on the horizon.

Enhancement as a Practice

#

The most important section is this one, because it reframes enhancement from an event to a practice. Enhancement is not an intervention you do once. It is a way of living that accumulates benefit over time.

Exercise produces structural brain changes after months of consistent effort. Sleep hygiene produces glymphatic benefit every night. Dietary patterns produce metabolic benefit that compounds over years. Cognitive engagement through the preserved-capacity activities from BML-05.13 produces neural activity that maintains and strengthens existing networks. Social engagement produces the complex neural activation that BML-05.15 documents.

None of these work in isolation. None of them work once. The person who exercises, sleeps well, eats a Mediterranean-pattern diet, engages cognitively through preserved expertise, and maintains social connection is not doing five separate interventions. They are building a practice that affects the brain through five different mechanisms simultaneously. The compound effect is greater than any single intervention, and the cost is a pair of walking shoes and the discipline to use them.

Dr. Ahmadi’s Patients

#

Two years of informal tracking. The patients who exercised consistently, addressed their sleep, and did not spend money on supplements have maintained cognitive function longer than the patients who bought supplements and remained sedentary. Dr. Ahmadi cannot claim the exercise prevented anything. She can show the trajectories.

The difference is not dramatic. It is not the difference between dementia and no dementia. It is the difference between a trajectory that declined at the expected rate and a trajectory that declined more slowly, preserving six months or a year of function that the expected trajectory would have consumed. Six months of preserved function is six months of independence, of living at home, of making one’s own decisions, of being the person the disease has not yet taken.

That is what a good pair of walking shoes buys. Not a cure. Not a reversal. Time. And time, when the currency is cognitive function, is the most valuable thing Dr. Ahmadi’s prescription pad can provide.